Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (207)	8/13/2003 5:38:18 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 447

Goddard: The 10-Q is out. There is no mention of Solvay. Why? Is not initiation of clinical trials with SLV320 a material event? There is no mention of the GPCR program in the same breath as diabetes. Why? The two used to be mentioned in pair. You should not continue only one portion of the thread without an explanation. What is mentioned?? We have created a subsididary for our diabetes and obesity programs. Our diabetes program includes a partnership with the Vanderbilt University Diabetes Center, a funded alliance with Tanabe Seiyaku Co. Ltd., and six proprietary gene-targeted discovery programs in the lead seeking and lead optimization phases, primarily focused in the glucose regulation and obesity fields. We have also transferred to this entity our existing diabetes teams comprised of approximately 25 employees. We are currently seeking a partner for the venture. If we are unable to obtain external funding for this newly formed entity, we will consider other alternatives to discontinue the diabetes program, including out-licensing our diabetes assets and reducing our employee headcount.